Clinical Trials Logo

Drug-induced Obesity clinical trials

View clinical trials related to Drug-induced Obesity.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01794429 Completed - Obesity Clinical Trials

Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue

TAO
Start date: February 2013
Phase: Phase 3
Study type: Interventional

To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic spectrum. The investigators will also examine possible associations between GLP-1 treatment and peripheral metabolic parameters such as change in body fat and HbA1c. Moreover, the GLP-1 analogue treatment will be associated with the effects/changes on cognition and subjective quality of life. Possible cerebral effects (pro-cognitive) of the GLP-1 analogue treatment will associated and correlated with changes in the brain, functional magnetic resonance imaging (fMRI).